Biologically Active Small Molecules

Reversibly inhibits dihyroorotate dehydrogenase, the rate-limiting step in the de novo synthesis of pyrimidines, preventing DNA synthesis of activated lymphocytes (IC₅₀s = 0.09, 3.

Reversibly inhibits dihyroorotate dehydrogenase, the rate-limiting step in the de novo synthesis of pyrimidines, preventing DNA synthesis of activated lymphocytes (IC₅₀s = 0.09, 3.

Mas antagonist that inhibits signaling by angiotensin (1-7), preventing vasodilation and insulin sensitization.

Mas antagonist that inhibits signaling by angiotensin (1-7), preventing vasodilation and insulin sensitization.

Mas antagonist that inhibits signaling by angiotensin (1-7), preventing vasodilation and insulin sensitization.

A sodium channel blocker with high-affinity and selectivity for inhibiting human Nav1.8 sodium channels (IC50 = 8 nM when stimulated at half-maximal inactivation and IC50 = 79 nM at a resting state) dose dependently reduces behavioral responses in

A sodium channel blocker with high-affinity and selectivity for inhibiting human Nav1.8 sodium channels (IC50 = 8 nM when stimulated at half-maximal inactivation and IC50 = 79 nM at a resting state) dose dependently reduces behavioral responses in

A sodium channel blocker with high-affinity and selectivity for inhibiting human Nav1.8 sodium channels (IC50 = 8 nM when stimulated at half-maximal inactivation and IC50 = 79 nM at a resting state) dose dependently reduces behavioral responses in

A sodium channel blocker with high-affinity and selectivity for inhibiting human Nav1.8 sodium channels (IC50 = 8 nM when stimulated at half-maximal inactivation and IC50 = 79 nM at a resting state) dose dependently reduces behavioral responses in

A potent and selective competitive antagonist of the P2X₇ receptor.

A potent and selective competitive antagonist of the P2X₇ receptor.

A potent and selective competitive antagonist of the P2X₇ receptor.